Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria.

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Giménez Arnau, Anna Mariaca
• dc.contributor.author Toubi, Eliasca
• dc.contributor.author Marsland, Alexanderca
• dc.contributor.author Maurer, Marcusca
• dc.date.accessioned 2017-01-13T09:46:34Z
• dc.date.issued 2016
• dc.description.abstract This supplement reports proceedings of the second international Global Urticaria Forum, which was held in Berlin, Germany in November 2015. Omalizumab is approved for the treatment of chronic spontaneous urticaria (CSU) in adult and adolescent (12 years and above) patients with inadequate response to/who remain symptomatic despite H1 -antihistamine treatment, and has demonstrated good efficacy and safety in the clinical trial setting. Real-life clinical experience with omalizumab can be explored to address important practical questions relating to its use in CSU patients. Some experts have proposed that a consensus algorithm, covering various aspects to consider when using omalizumab in real-life clinical practice for the management of CSU, could answer many of these questions.ca
• dc.description.sponsorship This supplement was funded by Novartis Pharma AG. It is a publication of the Novartis supported medicaleducation meeting that took place in Berlin in November 2015.
• dc.format.mimetype application/pdfca
• dc.identifier.citation Giménez-Arnau AM, Toubi E, Marsland AM, Maurer M. et al. Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria. J Eur Acad Dermatol Venereol. 2016 Jul;30 Suppl 5:25-32. doi: 10.1111/jdv.13697ca
• dc.identifier.doi http://dx.doi.org/10.1111/jdv.13697
• dc.identifier.issn 0926-9959
• dc.identifier.uri http://hdl.handle.net/10230/27887
• dc.language.iso engca
• dc.publisher Willeyca
• dc.relation.ispartof Journal of the European Academy of Dermatology and Venereology. 2016 Jul;30 Suppl 5:25-32
• dc.rights This is the pre-peer reviewed version of the following article:Giménez-Arnau AM, Toubi E, Marsland AM, Maurer M. et al. Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria. J Eur Acad Dermatol Venereol. 2016 Jul;30 Suppl 5:25-32, which has been published in final form at http://dx.doi.org/10.1111/jdv.13697. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.ca
• dc.rights.accessRights info:eu-repo/semantics/openAccessca
• dc.subject.other Urticària -- Tractamentca
• dc.title Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria.ca
• dc.type info:eu-repo/semantics/articleca
• dc.type.version info:eu-repo/semantics/acceptedVersionca